The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies
Open accessAbstract
The blood-brain barrier (BBB) limits brain uptake of therapeutic antibodies. It is believed that the BBB is disrupted in Alzheimer's disease (AD), potentially increasing drug permeability de facto. Here we compared active versus passive brain uptake of systemically dosed antibodies (anti-transferrin receptor [TfR] bispecific versus control antibody) in mouse models of AD. We first confirmed BBB disruption in a mouse model of multiple sclerosis as a positive control. Importantly, we found that BBB permeability was vastly spared in mouse models of AD, including PS2-APP, Tau transgenics, and APOE4 knockin mice. Brain levels of TfR in mouse models or in human cases of AD resembled controls, suggesting target engagement of TfR bispecific is not limited. Furthermore, infarcts from human AD brain showed similar occurrences compared to age-matched controls. These results question the widely held view that the BBB is largely disrupted in AD, raising concern about assumptions of drug permeability in disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although some studies have shown that ApoE4 disrupts BBB integrity in non-APP mice, it was recently reported that non-APP ApoE4 knock-in mice do not have any widespread BBB disruption [27].”
From Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease (2017) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 3×
“However, BBB impairments may exist in non-amyloid-depositing AD models such as APOE4 mice (Bell et al., 2012) or mutant human tau transgenic mice (Blair et al., 2015).”
BackgroundMethodBlood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
Toledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794
Self-citationBlood brain barrier: ageing and microvascular disease-systematic review and meta-analysis
Farrall, A., & Wardlaw, J. M. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.089 · Cited by 640
Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease
Erickson, M. A., & Banks, W. A. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.135 · Cited by 572
Tau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495
Flagged first, then by citations
Cited by
Sorted by citations
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0228-7 · Cited by 1,425
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“measured levels of transferrin receptor in brain samples from both AD animal models and AD patients, and did not observe any decreases [48].”
ResultBlood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
The blood–brain barrier in health and disease: Important unanswered questions
Profaci, C. P., Munji, R. N., Pulido, R. S., & Daneman, R. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190062 · Cited by 811
Alzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
The role of peripheral immune cells in the CNS in steady state and disease
Prinz, M., & Priller, J. (2017) · Nature Neuroscience · doi:10.1038/nn.4475 · Cited by 657
Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics
Petersen, M. A., Ryu, J. K., & Akassoglou, K. (2018) · Nature reviews. Neuroscience · doi:10.1038/nrn.2018.13 · Cited by 527
Merlini, M., Rafalski, V. A., Rios Coronado, P. E., Gill, T. M., Ellisman, M., Muthukumar, G., Subramanian, K. S., Ryu, J. K., Syme, C. A., Davalos, D., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.01.014 · Cited by 431
Lochhead, J. J., Yang, J., Ronaldson, P. T., & Davis, T. P. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00914 · Cited by 445
Yousef, H., Czupalla, C. J., Lee, D., Chen, M. B., Burke, A. N., Zera, K. A., Zandstra, J., Berber, E., Lehallier, B., Mathur, V., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0440-4 · Cited by 442
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 379
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Untangling the brain’s neuroinflammatory and neurodegenerative transcriptional responses
Srinivasan, K., Friedman, B. A., Larson, J. L., Lauffer, B. E., Goldstein, L. D., Appling, L. L., Borneo, J., Poon, C., Ho, T., Cai, F., et al. (2016) · Nature Communications · doi:10.1038/ncomms11295 · Cited by 336
Cerebrovascular disease in ageing and Alzheimer’s disease
Love, S., & Miners, J. S. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1522-0 · Cited by 299
Healthy aging and the blood–brain barrier
Banks, W. A., Reed, M. J., Logsdon, A. F., Rhea, E. M., & Erickson, M. A. (2021) · Nature Aging · doi:10.1038/s43587-021-00043-5 · Cited by 310
Ultrasound treatment of neurological diseases — current and emerging applications
Leinenga, G., Langton, C. M., Nisbet, R. M., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 274
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
Senatorov, V. V., Friedman, A. R., Milikovsky, D. Z., Ofer, J., Saar-Ashkenazy, R., Charbash, A., Jahan, N., Chin, G., Mihaly, E., Lin, J. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8283 · Cited by 257
Janelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.017 · Cited by 237
Brain Endothelial Cells Are Exquisite Sensors of Age-Related Circulatory Cues
Chen, M. B., Yang, A. C., Yousef, H., Lee, D., Chen, W., Schaum, N., Lehallier, B., Quake, S. R., & Wyss-Coray, T. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.012 · Cited by 233
“Indeed, while age-related BBB dysfunction has been probed with a diverse toolkit of tracers (Bien-Ly et al., 2015; Marques et al., 2013; Montagne et al., 2015; Mooradian, 1988), the transcriptional response of vessel segment-specific BECs to aging and changes in the systemic environment have not yet been explored in-d…”
The role of APOE in cerebrovascular dysfunction
Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W. J., & Bu, G. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1547-z · Cited by 231
Huynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
Intracellular transport and regulation of transcytosis across the blood–brain barrier
Villaseñor, R., Lampe, J., Schwaninger, M., & Collin, L. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2982-x · Cited by 221
Li, J. J., Wang, B., Kodali, M. C., Chen, C., Kim, E., Patters, B. J., Lan, L.-B., Kumar, S., Wang, X., Yue, J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1038-8 · Cited by 210
Cedernaes, J., Osorio, R. S., Varga, A. W., Kam, K., Schiöth, H. B., & Benedict, C. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.02.002 · Cited by 211
Age-Associated Changes in the Immune System and Blood–Brain Barrier Functions
Erickson, M. A., & Banks, W. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071632 · Cited by 203
Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease
Liao, F., Yoon, H., & Kim, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000383 · Cited by 191
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 172
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Johnsen, K. B., Bak, M., Kempen, P. J., Melander, F., Burkhart, A., Thomsen, M. S., Nielsen, M. S., Moos, T., & Andresen, T. L. (2018) · Theranostics · doi:10.7150/thno.25228 · Cited by 161
In vitro modeling of the neurovascular unit: advances in the field
Bhalerao, A., Sivandzade, F., Archie, S. R., Chowdhury, E. A., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00183-7 · Cited by 154
Cerebrovascular pathology during the progression of experimental Alzheimer's disease
Giannoni, P., Arango-Lievano, M., das Neves, I., Rousset, M.-C., Baranger, K., Rivera, S., Jeanneteau, F. D., Claeysen, S., & Marchi, N. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.001 · Cited by 152
Millan, M. J. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.004 · Cited by 151
Li, T., Vandesquille, M., Koukouli, F., Dudeffant, C., Youssef, I., Lenormand, P., Ganneau, C., Maskos, U., Czech, C., Grueninger, F., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.019 · Cited by 143
Johnsen, K. B., & Moos, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.032 · Cited by 134
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Maezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients
Skillbäck, T. B., Delsing, L., Synnergren, J., Mattsson, N., Janelidze, S., Nägga, K., Kilander, L., Hicks, R., Wimo, A. B., Winblad, B. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.028 · Cited by 127
Jin, W., Shen, L., Bu, X., Zhang, W., Chen, S., Huang, Z., Xiong, J., Gao, C., Dong, Z., He, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1721-y · Cited by 121
Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies
Liao, J., Fan, L., Li, Y., Xu, Q.-Q., Xiong, L., Zhang, S., Liu, J.-H., Xiao, Z.-C., Zhang, C., Yang, J., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.009 · Cited by 119
The blood brain barrier in Alzheimer’s disease
Chakraborty, A., de Wit, N. M., van der Flier, W. M., & de Vries, H. E. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2016.11.008 · Cited by 118
Park, J., Baik, S. H., Han, S., Cho, H. J., Choi, H., Kim, H. J., Choi, H., Lee, W., Kim, D. K., & Mook‐Jung, I. (2016) · Aging Cell · doi:10.1111/acel.12530 · Cited by 115
Sun, M., Ma, K., Wen, J., Wang, G., Zhang, C., Li, Q., Bao, X., & Wang, H. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190872 · Cited by 113
Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 109
Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives
Kouhi, A., Pachipulusu, V., Kapenstein, T., Hu, P., Epstein, A. L., & Khawli, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126442 · Cited by 109
NAD+ rescues aging-induced blood-brain barrier damage via the CX43-PARP1 axis
Zhan, R., Meng, X., Tian, D., Xu, J., Cui, H., Yang, J., Xu, Y., Shi, M., Xue, J., Yu, W., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.08.010 · Cited by 109
Peripherally derived FGF21 promotes remyelination in the central nervous system
Kuroda, M., Muramatsu, R., Maedera, N., Koyama, Y., Hamaguchi, M., Fujimura, H., Yoshida, M., Konishi, M., Itoh, N., Mochizuki, H., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94337 · Cited by 101
Bourassa, P., Alata, W., Tremblay, C., Paris‐Robidas, S., & Calon, F. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00870 · Cited by 99
Ou, W., Yang, J., Simanauskaite, J., Choi, M. K., Castellanos, D. M., Chang, R., Sun, J., Jagadeesan, N., Parfitt, K. D., Cribbs, D. H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02332-7 · Cited by 101
Neuropathology of White Matter Lesions, Blood–Brain Barrier Dysfunction, and Dementia
Hainsworth, A. H., Minett, T., Andoh, J., Forster, G., Bhide, I., Barrick, T. R., Elderfield, K., Jeevahan, J., Markus, H. S., & Bridges, L. (2017) · Stroke · doi:10.1161/strokeaha.117.018101 · Cited by 95
Kumar, N. N., Lochhead, J. J., Pizzo, M. E., Nehra, G., Boroumand, S., Greene, G., & Thorne, R. G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.006 · Cited by 95
Application of quercetin in neurological disorders: from nutrition to nanomedicine
Jajin, E. A., Esmaeili, A., Rahgozar, S., & Noorbakhshnia, M. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0080 · Cited by 94
Oikari, L. E., Pandit, R., Stewart, R., Cuní‐López, C., Quek, H., Sutharsan, R., Rantanen, L. M., Oksanen, M., Lehtonen, Š., de Boer, C. M., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.011 · Cited by 87
Yamazaki, Y., Shinohara, M., Yamazaki, A., Ren, Y., Asmann, Y. W., Kanekiyo, T., & Bu, G. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313169 · Cited by 89
Rifaai, R. A., Mokhemer, S. A., Saber, E. A., El‐Aleem, S. A. A., & El‐Tahawy, N. F. G. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101795 · Cited by 94
The blood–brain and gut–vascular barriers: from the perspective of claudins
Scalise, A. A., Kakogiannos, N., Zanardi, F., Iannelli, F., & Giannotta, M. (2021) · Tissue Barriers · doi:10.1080/21688370.2021.1926190 · Cited by 86
Vulnerability of the Hippocampus to Insults: Links to Blood–Brain Barrier Dysfunction
Davidson, T. L., & Stevenson, R. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041991 · Cited by 80
Vascular and Neurogenic Rejuvenation in Aging Mice by Modulation of ASM
Park, M., Lee, J. Y., Park, K. H., Jung, I. K., Kim, K., Lee, Y., Ryu, H.-H., Jeong, Y., Kang, M., Schwaninger, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.010 · Cited by 74
Water-exchange MRI detects subtle blood-brain barrier breakdown in Alzheimer's disease rats
Dickie, B., Vandesquille, M., Ulloa, J. L., Boutin, H., Parkes, L. M., & Parker, G. J. M. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.09.030 · Cited by 71
Engineering antibody and protein therapeutics to cross the blood–brain barrier
Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 75
Chowdhury, E. A., Noorani, B., Alqahtani, F., Bhalerao, A., Raut, S., Sivandzade, F., & Cucullo, L. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20985946 · Cited by 77
Roberts, B. R., Doecke, J. D., Rembach, A., Yévenes, L. F., Fowler, C. J., McLean, C., Lind, M., Volitakis, I., Masters, C. L., Bush, A. I., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0390-8 · Cited by 67
Goldwaser, E. L., Acharya, N. K., Sarkar, A., Godsey, G. A., & Nagele, R. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160284 · Cited by 64
Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice
Leinenga, G., & Götz, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00055 · Cited by 66
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Gallo, M., Defaus, S., & Andreu, D. (2018) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.11.010 · Cited by 66
Chiquita, S., Ribeiro, M., Castelhano, J., Oliveira, F., Sereno, J., Batista, M., Abrunhosa, A., Rodrigues-Neves, A. C., Carecho, R., Baptista, F., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz045 · Cited by 63
Metabolic Syndrome and the Cellular Phase of Alzheimer's Disease
Pugazhenthi, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2016.12.016 · Cited by 65
Shukla, A., McIntyre, L. L., Marsh, S. E., Schneider, C. A., Hoover, E. M., Walsh, C. M., Lodoen, M. B., Blurton-Jones, M. M., & Inlay, M. A. (2018) · Glia · doi:10.1002/glia.23575 · Cited by 59
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 60
Παπαδιά, Κ., Giannou, A. D., Markoutsa, E., Bigot, C., Vanhoute, G., Mourtas, S., der Linded, A. V., Stathopoulos, G. T., & Antimisiaris, S. G. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.010 · Cited by 56
Keifer, J. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25022 · Cited by 57
Nagaraj, S., Want, A., Laskowska-Kaszub, K., Fesiuk, A., Vaz, S., Logarinho, E., & Wojda, U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073653 · Cited by 56
Molecular Insight into the Therapeutic Promise of TargetingAPOE4for Alzheimer’s Disease
Mamun, A. A., Uddin, M. S., Bashar, M. F. B., Zaman, S., Begum, Y., Bulbul, I. J., Islam, M. S., Sarwar, M. S., Mathew, B., Amran, M. S., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5086250 · Cited by 54
Wu, S., Liu, H., Zhao, H., Wang, X., Chen, J., Xia, D., Chen, X., Cheng, J., Zhao, Z., & He, Y. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.11.009 · Cited by 51
Cerebrovascular phenotypes in mouse models of Alzheimer’s disease
Szu, J. I., & Obenaus, A. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x21992462 · Cited by 49
de Retana, S. F., Cano‐Sarabia, M., Marazuela, P., Sánchez‐Quesada, J. L., García‐León, A., Montañola, A., Montaner, J., Maspoch, D., & Hernández‐Guillamón, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15215-w · Cited by 49
Site-specific opening of the blood-brain barrier by extracellular histones
Villalba, N., Baby, S., Cha, B. J., & Yuan, S. Y. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01950-x · Cited by 48
Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer’s disease
D'Cunha, N. M., McKune, A. J., Panagiotakos, D. B., Georgousopoulou, E. N., Thomas, J., Mellor, D. D., & Naumovski, N. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1349032 · Cited by 47
Pulse Pressure: An Emerging Therapeutic Target for Dementia
Levin, R., Carnegie, M. H., & Celermajer, D. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00669 · Cited by 48
Dickie, B., Boutin, H., Parker, G. J. M., & Parkes, L. M. (2021) · NMR in Biomedicine · doi:10.1002/nbm.4510 · Cited by 45
Focused ultrasound as a novel strategy for Alzheimer disease therapeutics
Meng, Y., Volpini, M., Black, S. E., Lozano, A. M., Hynynen, K., & Lipsman, N. (2017) · Annals of Neurology · doi:10.1002/ana.24933 · Cited by 45
Gustafsson, S. S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund‐Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
Cummings, D. M., Benway, T. A., Ho, H., Tedoldi, A., Freitas, M. M. F., Shahab, L., Murray, C. E., Richard-Loendt, A., Brandner, S., Lashley, T., et al. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx046 · Cited by 42
Gustafsson, S. S., Lindström, V., Ingelsson, M., Hammarlund‐Udenaes, M., & Syvänen, S. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.002 · Cited by 39
Multifunctional LUV Liposomes Decorated for BBB and Amyloid Targeting. A. In Vitro Proof-of-Concept
Papadia, K., Markoutsa, E., Mourtas, S., Giannou, A. D., La Ferla, B., Nicotra, F., Salmona, M., Klepetsanis, P., Stathopoulos, G. T., & Antimisiaris, S. G. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.019 · Cited by 40
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 43
Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer's disease
Šimić, G., Španić, E., Horvat, L. L., & Hof, P. R. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.003 · Cited by 40
Sun, B., Li, L., Harris, O. A., & Luo, J. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00478-5 · Cited by 44
Nogo-A Antibodies for Progressive Multiple Sclerosis
Ineichen, B. V., Plattner, P. S., Good, N., Martinꝉ, R., Linnebank, M., & Schwab, M. E. (2017) · CNS Drugs · doi:10.1007/s40263-017-0407-2 · Cited by 37
Epidermal growth factor prevents oligomeric amyloid-β induced angiogenesis deficits in vitro
Koster, K. P., Thomas, R., Morris, A. W. J., & Tai, L. M. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16669956 · Cited by 36
Interaction between APOE genotype and diabetes in cognitive decline
Shinohara, M., Tashiro, Y., Suzuki, K., Fukumori, A., Bu, G., & Sato, N. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12006 · Cited by 36
Zhao, Y., Suo, Y., Yang, Z., Hao, Y., Li, W., Su, Y., Shi, Y., Gao, Y., Song, L., Yin, X., et al. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.009 · Cited by 39
Fibrinogen Chains Intrinsic to the Brain
Golanov, E. V., Sharpe, M. A., Regnier‐Golanov, A., del Zoppo, G. J., Baskin, D. S., & Britz, G. W. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00541 · Cited by 35
Matsuki, H., Mandai, S., Shiwaku, H., Koide, T., Takahashi, N., Yanagi, T., Inaba, S., Ida, S., Fujiki, T., Mori, Y., et al. (2023) · Aging · doi:10.18632/aging.205164 · Cited by 37
Ceci, C., Lacal, P. M., Barbaccia, M. L., Mercuri, N. B., Graziani, G., & Ledonne, A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107101 · Cited by 36
Schurman, C. A., Burton, J. B., Rose, J., Ellerby, L., Alliston, T. N., & Schilling, B. (2023) · Journal of Bone Metabolism · doi:10.11005/jbm.2023.30.1.1 · Cited by 33
Nanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases
Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 36
Zhukov, O., He, C., Soylu-Kucharz, R., Cai, C., Lauritzen, A. D., Aldana, B. I., Björkqvist, M., Lauritzen, M., & Kucharz, K. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1089005 · Cited by 30
Li, K., Luo, X., Zeng, Q., Jiaerken, Y., Wang, S., Xu, X., Xu, X., Xu, J., Wang, C., Zhou, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55452-9 · Cited by 31
Metadata
- Authors
- Bien-Ly, N., Boswell, C. A., Jeet, S., Beach, T. G., Hoyte, K., Luk, W., Shihadeh, V., Ulufatu, S., Foreman, O., Lu, Y., DeVoss, J., van der Brug, M., & Watts, R. J.
- Affiliations
- Genentech (US)
- Banner Sun Health Research Institute (US)
- Corresponding author
- van der Brug, Marcel
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 88
- Issue
- 2
- Pages
- 289-297
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W2158547909
- Cited by
- 198
- References
- 40
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 12 · 2023: 17 · 2022: 15 · 2021: 24 · 2020: 16 · 2019: 25 · 2018: 18 · 2017: 25 · 2016: 19 · 2015: 4
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, Alzheimer's disease, therapeutic antibodies, transferrin receptor, bispecific antibodies, blood-brain barrier permeability, APP transgenic mice, tau transgenic mice, infarction, drug permeability
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Blood-Brain Barrier, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Recombinant Fusion Proteins, Mice, Knockout, Mice, Single-Chain Antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
